Herein, we report the translational development and validation of BAFF-R CAR T cells produced under current good manufacturing practices (cGMP) intended for use in a first-in-human Phase 1 trial for BAFF-R-positive relapsed/refractory (r/r) B-ALL. The gene discussed is TNFRSF13C; the disease is acute lymphoblastic leukemia.